|
|
|
|
|
|
|
|
|
18.08.25 - 22:36
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 15, 2025, it granted stock options to purchase shares of common stock to Elizabeth Mellen, the Company's newly-appointed Chief Regulatory Officer, and one other new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted Ms. Mellen stock options to purchase 270,000 shares of common stock. The stock options that were granted have an exercise price of $18.21 per share, which is equal to the closing price of Stoke's common stock on August 15, 2025. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's opt...
|
|
|
|
|
13.08.25 - 22:48
|
Where Stoke Therapeutics Stands With Analysts (Benzinga)
|
|
|
Latest Ratings for STOK
DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
View More Analyst Ratings for STOK
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
12.08.25 - 22:06
|
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
|
|
|
– First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome –
– New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated –
– Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder –
– As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness –
– Webcast and conference call for analysts and investors at 4:30PM Eastern Time today –BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-...
|
|
|
|
|
07.08.25 - 13:03
|
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates.
The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. An archived replay of the webcast will be available for at least 90 days following the event.
Ab...
|
|
|
|
|
|
|
16.07.25 - 22:36
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2025, it granted stock options to purchase shares of common stock to Sara Den Besten, the Company's newly-appointed Chief People Officer, and two other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted Ms. Den Besten stock options to purchase 260,000 shares of common stock. The stock options that were granted have an exercise price of $11.75 per share, which is equal to the closing price of Stoke's common stock on July 15, 2025. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option ...
|
|
|
|
|
17.06.25 - 22:33
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 16, 2025, it granted stock options to purchase an aggregate of 37,200 shares of common stock to two new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise price of $11.70 per share, which is equal to the closing price of Stoke's common stock on June 16, 2025. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48t...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
